Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Thyroid Cancer

Aliases
Thyroid Carcinoma, Thyroid Gland Carcinoma

114 clinical trials

110 products

23 drugs

Clinical trial
A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor
Status: Recruiting, Estimated PCD: 2024-09-01
Product
MDX2001
Clinical trial
A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-08-01
Product
Trametinib
Product
XP-102
Clinical trial
A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
TT-00420
Product
Atezolizumab
Product
Nab-Paclitaxel
Product
Tovorafenib
Clinical trial
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations
Status: Recruiting, Estimated PCD: 2025-07-31
Product
Pimasertib
Clinical trial
A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Status: Recruiting, Estimated PCD: 2025-10-23
Product
encorafenib
Product
PF-07799544
Product
PF-07799933
Clinical trial
Phase I/II Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For Recombinant Human Thyroid Stimulating Hormone In Post-thyroidectomized Patients
Status: Completed, Estimated PCD: 2020-12-29
Product
Recombinant Human Thyroid Stimulating Hormone
Clinical trial
An Open, Single-arm, Self-controlled, Multi-center Phase 3 Study to Compare the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
Status: Completed, Estimated PCD: 2023-07-05
Product
rhTSH
Clinical trial
A Phase 1 Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation Refractory to Selective RET Inhibitors
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
LOXO-260
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Status: Active (not recruiting), Estimated PCD: 2020-08-19
Product
Cabozantinib
Product
Placebo
Clinical trial
A First-in-Human (FiH) Study of IK-595, an Oral Dual MEK/RAF Inhibitor, in Patients With RAS-or RAF-altered Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-07-01
Product
IK-595
Product
JK08
Clinical trial
A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, Monotherapy or in Combination in Patients With Unresectable Locally Advanced or Metastatic Cancer
Status: Recruiting, Estimated PCD: 2025-10-17
Product
Pembrolizumab
Clinical trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS
Status: Recruiting, Estimated PCD: 2027-07-29
Product
binimetinib
Product
cetuximab
Product
BDTX-4933
Clinical trial
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-06-01
Clinical trial
A Phase 1, Open-label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive Neoplasms
Status: Recruiting, Estimated PCD: 2026-06-01
Product
SNS-101
Product
Cemiplimab
Product
pembrolizumab
Clinical trial
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
Status: Recruiting, Estimated PCD: 2027-05-04
Product
Vandetanib
Clinical trial
A Randomized, Double Blind, Placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Vandetanib (ZD6474) in Patients With Locally Advanced or Metastatic Papillary or Follicular Thyroid Carcinoma Failing or Unsuitable for Radioiodine Therapy
Status: Completed, Estimated PCD: 2009-12-02
Product
Sorafenib
Clinical trial
Drug Use Investigation of Sorafenib/ NEXAVAR® for Unresectable Differentiated Thyroid Carcinoma (DTC)
Status: Active (not recruiting), Estimated PCD: 2020-02-27
Product
ST-1898
Clinical trial
A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Status: Completed, Estimated PCD: 2024-03-21
Clinical trial
A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of ST-1898 Tablets in Patients With Locally Advanced or Metastatic RAIR-DTC After Failure of at Least First-line TKI Systemic Therapy
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Pralsetinib
Clinical trial
Expanded Access of LOXO-260 in Participants With RET Mutant or RET Fusion Tumors Refractory to Prior RET Selective TKI Treatment
Status:
Clinical trial
RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors
Status: Completed, Estimated PCD: 2020-06-10
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC)
Status: Recruiting, Estimated PCD: 2027-05-26
Product
Dabrafenib
Product
Anlotinib Hydrochloride
Clinical trial
A Real-world Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
Status: Recruiting, Estimated PCD: 2027-08-01
Product
ZD6474
Product
Lenvatinib
Clinical trial
Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma
Status: Completed, Estimated PCD: 2019-07-18
Product
Etoposide
Product
Ifosfamide
Clinical trial
An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2009-07-31
Product
AL2846
Product
Multikinase inhibitors
Clinical trial
Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of AL2846 Capsule in Iodine-resistant Differentiated Thyroid Cancer With Previous TKI Treatment Failure
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease
Status: Active (not recruiting), Estimated PCD: 2014-04-02
Clinical trial
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
APL-101
Clinical trial
A Phase II Study of the Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
Status: Terminated, Estimated PCD: 2022-05-16
Product
Alectinib
Product
cabozantinib
Product
atezolizumab
Product
KVA12123
Clinical trial
A Phase 1/2 Open-label Trial of KVA12123 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Status:
Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer
Status: Completed, Estimated PCD: 2013-11-15
Product
Ulixertinib
Clinical trial
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-07-01
Product
KVA12123 Plus Pembrolizumab
Product
Systemic Treatment
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Randomized, Open-label, Multi-center, Controlled Phase Ⅲ Study to Evaluate the Safety and Efficacy of Recombinant Human Thryoid Stimulating Hormone（rhTSH） for Adjuvant Radioiodine Ablation Therapy in Postoperative Patients With Differentiated Thyroid Cancer
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.
Status: Completed, Estimated PCD: 2015-08-30
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors
Status: Completed, Estimated PCD: 2021-11-12
Product
Enapotamab vedotin
Product
TH1902
Clinical trial
A Phase 1, Open-Label, Dose Escalation and Expansion Study of TH1902 in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System of Patients Following Radioiodine Therapy for Thyroid Carcinoma
Status: Terminated, Estimated PCD: 2023-09-25
Product
Artificial Tears
Clinical trial
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Completed, Estimated PCD: 2018-12-31
Clinical trial
A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Drug
Regorafenib
Clinical trial
Studies on Thyroid Nodules and Thyroid Cancer
Status:
Product
68-Gallium Dotatate
Clinical trial
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)
Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers
Status: Active (not recruiting), Estimated PCD: 2021-08-25
Clinical trial
An Open-Label, Non-Randomized, Dose Escalation, Single-Center, Investigator-Initiated Trial to Determine the Safety, Dosimetry, and Preliminary Effectiveness of 177Lu-DOTA-EB-FAPI in Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With Progressive Disease After Tyrosine Kinase Inhibitors Treatment
Status: Recruiting, Estimated PCD: 2024-06-15
Product
177Lu-DOTA-EB-FAPI 2
Product
177Lu-DOTA-EB-FAPI
Clinical trial
Phase I Investigator-initiated Clinical Trial in Patients With Differentiated Thyroid Cancer (Papillary Cancer, Follicular Cancer) by the Targeted Alpha Therapy Drug TAH-1005 ([211At] NaAt) (Alpha-T1 Study)
Status: Recruiting, Estimated PCD: 2025-03-31
Product
Targeted alpha therapy
Clinical trial
A Phase II Study to Explore the Safety and Efficacy of Multiple Target Kinase Inhibitor(mTKI) Combined With Anti-Programmed Death-1(PD-1) Antibody in the Treatment of Advanced Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2023-12-15
Product
Multiple Tyrosine Kinase Inhibitor (mTKI) + Anti-PD-1 Antibody
Clinical trial
Encorafenib/Binimetinib With or Without Nivolumab for Patients With Metastatic BRAF V600 Mutant Thyroid Cancer
Status: Recruiting, Estimated PCD: 2024-10-30
Product
Binimetinib
Product
Encorafenib
Clinical trial
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Status: Completed, Estimated PCD: 2022-04-28
Product
MLN0128
Product
Nivolumab
Clinical trial
A Multicohort, Single-Centre, Phase II Trial of the Efficacy and Safety of Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer
Status: Not yet recruiting, Estimated PCD: 2024-11-15
Product
Famitinib + Adebrelimab
Clinical trial
High Frame Rate 3-D Super Resolution Ultrasound Microvascular Imaging
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Definity
Clinical trial
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
Status: Recruiting, Estimated PCD: 2026-08-01
Product
Iodine-124
Clinical trial
Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers
Status: Active (not recruiting), Estimated PCD: 2016-12-31
Product
Sunitinib
Clinical trial
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Thyrogen
Clinical trial
Observational Study on Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Gallium Ga 68 FAPi-46
Clinical trial
Clinical Efficacy and Safety Analysis of 125I Brachytherapy Combined With Anlotinib in Radioiodine Refractory Thyroid Carcinoma Patients
Status: Completed, Estimated PCD: 2024-04-01
Product
Iodine-125 Brachytherapy + Anlotinib
Clinical trial
Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers
Status: Active (not recruiting), Estimated PCD: 2023-02-06
Product
Durvalumab
Clinical trial
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Abemaciclib
Clinical trial
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Status: Recruiting, Estimated PCD: 2030-12-31
Product
Genetic screening
Clinical trial
Neoadjuvant Pembrolizumab in High-risk Thyroid Cancers
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
Pharmacodynamic Study of Vemurafenib in the Neoadjuvant Setting in Patients With Locally Advanced Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2026-09-30
Product
Vemurafenib
Clinical trial
A Phase 2 Study of Neoadjuvant Lenvatinib in Locally Advanced Invasive Thyroid Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Product
LENVATINIB
Clinical trial
Phase 1 Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2024-10-01
Product
IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Clinical trial
Optimal Dosing of Oral Anticancer Drugs in Older Adults With Cancer: a Randomized Pilot Study.
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Product
Olaparib
Product
Palbociclib
Product
Pazopanib
Clinical trial
Thyroid Cancer and Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW With Molecular Fluorescence Guided Surgery. Thyroid cAncer Surgery With Intraoperative Molecular fluoRescent Imaging to rEduce overtreatmenT and Morbidity
Status: , Estimated PCD: 2023-10-01
Product
Bevacizumab-IRDye800CW
Clinical trial
Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients With HIV Infection
Status: Active (not recruiting), Estimated PCD: 2025-11-02
Clinical trial
Neoadjuvant Treatment With Selpercatinib in RET-Altered Thyroid Cancers
Status: Recruiting, Estimated PCD: 2024-09-10
Product
Selpercatinib
Clinical trial
Clinical Outcome and Quality of Life in Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Product
RAI
Clinical trial
A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2024-02-20
Drug
Nab-Paclitaxel
Drug
T-VEC
Clinical trial
CLINICAL UTILITY AND FEASIBILITY OF I-124 PET/CT IMAGING AND DOSIMETRY IN PATIENTS WITH THYROID CANCER
Status: Recruiting, Estimated PCD: 2029-01-31
Product
I-124 PET/CT imaging
Clinical trial
Hereditary Risk Factors for Thyroid Cancer
Status: Recruiting, Estimated PCD: 2029-03-01
Product
Genetic Counselor
Clinical trial
The Use of Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Who Are Treated With Radioactive Iodine for Thyroid Cancer
Status: Recruiting, Estimated PCD: 2027-12-31
Product
Artificial Tears Methylcellulose
Clinical trial
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Status: Recruiting, Estimated PCD: 2029-10-01
Product
Cobimetinib
Clinical trial
Analysis of Parathyroid Vascularization During Total Thyroidectomy Using Quantitative Real-time Indocyanine Green Angiography
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Product
Indocyanine green
Clinical trial
A Multicenter, Open Label, Two Cohort, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of the Anti-TROP2 Antibody-drug Conjugate Sacituzumab Govitecan in Patients With Advanced Differentiated and Anaplastic Thyroid Neoplasms.
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Drug
Sacituzumab govitecan
Drug
cyclophosphamide
Drug
fludarabine
Clinical trial
A Phase Ib Trial of Vemurafenib Plus Copanlisib to Enhance Radioiodine Avidity in Radioiodine-Refractory Thyroid Cancers
Status: Completed, Estimated PCD: 2023-09-29
Product
Copanlisib
Clinical trial
177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.
Status: Recruiting, Estimated PCD: 2024-06-01
Product
177Lu-PP-F11N
Clinical trial
Molecular Analysis for Therapy Choice (MATCH)
Status: Active (not recruiting), Estimated PCD: 2025-12-31
Drug
Adavosertib
Clinical trial
Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2025-09-02
Product
Afatinib
Drug
Spartalizumab
Clinical trial
Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
Status: Completed, Estimated PCD: 2020-12-30
Drug
sorafenib
Clinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
Status: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study
Status: Completed, Estimated PCD: 2024-03-01
Clinical trial
Larotrectinib to Enhance RAI Avidity in Patients With Differentiated Thyroid Cancer Harboring NTRK Fusions
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Larotrectinib
Clinical trial
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer: an Open-label, Multicenter, Single-arm Study
Status: Recruiting, Estimated PCD: 2026-08-04
Drug
surufatinib
Clinical trial
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Product
Thyrotropin alpha
Clinical trial
Energy Metabolism in Thyroidectomized Patients
Status: Completed, Estimated PCD: 2023-04-19
Product
Levothyroxine
Product
Liothyronine
Drug
Varlilumab
Product
Tislelizumab
Clinical trial
IDEntification of New Predisposition Genes in Differentiated THYroid Cancer
Status: Active (not recruiting), Estimated PCD: 2026-02-01
Product
WGS
Clinical trial
Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and Trametinib
Status: Recruiting, Estimated PCD: 2024-06-20
Drug
Lurbinectedin
Clinical trial
Evaluation of Recurrence in Patients With Differentiated Thyroid Cancer
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
Lenvatinib in Combination With Pembrolizumab for Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
A Phase 1 Study of Dabrafenib in Combination With Lapatinib in BRAF Mutant Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
Lapatinib
Product
Lapatinib Ditosylate
Clinical trial
Prospective Comparison of the Effect on Antiadhesive Barriers During Thyroid or Parathyroid Surgery
Status: Recruiting, Estimated PCD: 2023-10-01
Product
Oxidized regenerated cellulose
Product
Hyaluronic acid
Drug
mFOLFOX6
Clinical trial
Health-related Quality of Life of Patients With Locally Advanced Thyroid Cancer Receiving Targeted Therapy
Status: Recruiting, Estimated PCD: 2025-01-31
Product
Tyrosine kinase inhibitor
Clinical trial
Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Status: Recruiting, Estimated PCD: 2024-11-01
Drug
Pembrolizumab (Keytruda)
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2020-03-25
Product
Apatinib
Clinical trial
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Status: Active (not recruiting), Estimated PCD: 2020-07-17
Product
Selumetinib
Clinical trial
[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) Positron Emission Tomography (PET) in Neuroendocrine Tumours
Status:
Product
6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
Status: Active (not recruiting), Estimated PCD: 2024-03-31
Product
Tipifarnib
Clinical trial
Phase II Study Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
Sorafenib with Everolimus
Clinical trial
Evaluation of The Development of Central Resistance to Thyroid Hormone After Prolonged Exposure to Excess Thyroid Hormone in Thyroid Cancer Patients
Status: Withdrawn, Estimated PCD: 2023-02-15
Product
Thyrotropin Releasing Hormone
Drug
levothyroxine
Clinical trial
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction
Status: Active (not recruiting), Estimated PCD: 2018-11-29
Product
Romidepsin
Clinical trial
Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas
Status: Active (not recruiting), Estimated PCD: 2025-07-31
Drug
Atezolizumab
Drug
Abraxane
Clinical trial
Thyroid Nodule Gene Sequencing in a Danish Population - A Pilot Study
Status: , Estimated PCD: 2023-12-31
Product
Molecular analyses
Drug
Tiragolumab
Clinical trial
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications
Status: Active (not recruiting), Estimated PCD: 2026-03-31
Drug
cetuximab
Product
Temsirolimus
Product
Valproic Acid
Clinical trial
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Status: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
Pilot Study of Metabolic Guidance for Therapy in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck
Status: Recruiting, Estimated PCD: 2027-05-31
Product
Hyperpolarized Carbon C 13 Pyruvate
Clinical trial
Multicentric Phase III Trial Comparing Two Strategies in Intermediate-risk Differentiated Thyroid Cancer Patients: Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up Based on Serum Tg Values and Diagnostic RAI Scintigraphy
Status: Recruiting, Estimated PCD: 2031-02-01
Product
Systematic RAI-treatment
Clinical trial
Selpercatinib to Enhance RAI Avidity in Children, Adolescents, and Young Adults With Newly Diagnosed Differentiated Thyroid Cancers Harboring RET Fusions
Status: Not yet recruiting, Estimated PCD: 2030-08-01
Clinical trial
Precision Medicine Applied to Locally Advanced Thyroid Cancer Using Tumor-derived Organoids and In-vitro Sensitivity Testing: a Phase 2a, Single-center, Open-label, and Non-comparative Study
Status: Recruiting, Estimated PCD: 2024-12-01
Drug
Anlotinib
Product
Donafenib
Product
Everolimus
Product
Dabrafenib + Trametinib
Drug
Entrectinib
Drug
Pralsetinib
Drug
Larotrectinib